RA
ZVRA icon

Royce & Associates’s Zevra Therapeutics ZVRA Stock Holding History

Royce & Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Sell
882,658
-106,016
-11% -$1.18M 0.1% 327
2026
Q1 		$9.21M Buy
988,674
+122,852
+14% +$1.11M 0.09% 353
2025
Q4 		$7.76M Buy
865,822
+174,583
+25% +$1.65M 0.08% 385
2025
Q3 		$6.57M Buy
+691,239
New +$6.93M 0.07% 406

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's ZVRA Position: Q2 2026 in Review

Royce & Associates reduced its Zevra Therapeutics (ZVRA) stake by 11% in Q2 2026, selling an estimated $1.18M and leaving 882,658 shares worth $12.7M. The position accounts for 0.1% of the portfolio, ranked #327.

Royce & Associates first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Royce & Associates held 882,658 shares of Zevra Therapeutics worth $12.7M as of Q2 2026.
  • Royce & Associates sold 106,016 Zevra Therapeutics shares in Q2 2026, an estimated $1.18M.
  • Zevra Therapeutics made up 0.1% of Royce & Associates's portfolio in Q2 2026, its #327 holding.
  • Royce & Associates first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.